Conjugated Via Claimed Linking Group, Bond, Chelating Agent, Or Coupling Agent (e.g., Conjugated To Proteinaceous Toxin Via Claimed Linking Group, Bond, Coupling Agent, Etc.) Patents (Class 424/179.1)
  • Patent number: 11261227
    Abstract: A glucagon derivative, a long-acting conjugate of the glucagon derivative, and a use thereof are disclosed.
    Type: Grant
    Filed: March 6, 2020
    Date of Patent: March 1, 2022
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Jung Kuk Kim, Young Jin Park, In Young Choi, Sung Youb Jung
  • Patent number: 11253586
    Abstract: Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
    Type: Grant
    Filed: March 18, 2021
    Date of Patent: February 22, 2022
    Assignee: Novavax, Inc.
    Inventors: Gale Smith, Michael J. Massare, Jing-Hui Tian
  • Patent number: 11236177
    Abstract: The invention relates to proximity-based sortase-mediated protein purification and ligation. Specifically, the invention relates to techniques that links protein expression/purification with conjugation to therapeutic agents, imaging agents, or linkers.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: February 1, 2022
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Andrew Tsourkas, Burcin Altun, Hejia Henry Wang, Feifan Yu
  • Patent number: 11149088
    Abstract: A polypeptide having a heavy chain variable region and/or light chain variable region that specifically binds to Axl protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region that bind to Axl protein. Pharmaceutical compositions and kits comprising the polypeptide or antibodies and antibody fragments containing the polypeptide are also provided.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: October 19, 2021
    Assignee: BioAtla, Inc.
    Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
  • Patent number: 11065319
    Abstract: Methods and products for diagnosing, treating and/or delaying onset of chronic allograft rejection, including cardiac allograft vasculopathy. In an exemplary embodiment of a noninvasive method of screening a cardiac allograft recipient for being at-risk for developing cardiac allograft vasculopathy of the present disclosure, the method comprises the steps of withdrawing at least one biological sample from a cardiac allograft recipient; and analyzing the at least one biological sample for one or more biomarkers indicative of the presence of fibrin deposits within the cardiac allograft microvasculature; wherein detection of the one or more biomarkers indicates that the cardiac allograft recipient is at-risk for or developing cardiac allograft vasculopathy.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: July 20, 2021
    Assignee: 3DT Holdings, LLC
    Inventors: Ghassan S. Kassab, Carlos A. Labarrere
  • Patent number: 10980890
    Abstract: Provided herein are compounds comprising a self-immolative group, and the compounds comprising a self-immolative group according to the present invention may include a protein (for example, an oligopeptide, a polypeptide, an antibody, or the like) having substrate-specificity for a target and an active agent (for example, a drug, a toxin, a ligand, a detection probe, or the like) having a specific function or activity.
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: April 20, 2021
    Assignee: LegoChem Biosciences, Inc.
    Inventors: Yong Zu Kim, Tae Kyo Park, Sung Ho Woo, Sun Young Kim, Jong Un Cho, Doo Hwan Jung, Ji Young Min, Hyang Sook Lee, Yun Hee Park, Jeong Hee Ryu, Kyu Man Oh, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Jeon Yang
  • Patent number: 10953089
    Abstract: Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
    Type: Grant
    Filed: August 19, 2020
    Date of Patent: March 23, 2021
    Assignee: NOVAVAX, INC.
    Inventors: Gale Smith, Michael J. Massare, Jing-Hui Tian
  • Patent number: 10894089
    Abstract: The present invention relates to insulin and/or an insulin analogue conjugate, and a use thereof, wherein the insulin and/or insulin analogue have improved in vivo durability and stability by linking the same with an Fc region of immunoglobulin. The insulin and/or an insulin analogue conjugate of the present invention show an in vivo activity similar to that of insulin. In addition, the insulin and/or insulin analogue conjugate of the present invention are long-acting formulations of insulin and/or the analogue thereof, in which serum half-life is remarkably increased, and therefore, the present invention provides remarkable insulin and/or an insulin analogue conjugate, which do not induce hypoglycemia, a drawback of insulin treatment.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: January 19, 2021
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Yong Ho Heo, Jong Soo Lee, Sung Hee Park, Dae Jin Kim, Sung Youb Jung, Se Chang Kwon
  • Patent number: 10871490
    Abstract: The invention is directed to a detection reagent for CAR expressing cells according to general formula (1) Xn—Sm—Do wherein X is a polypeptide comprising at least 20 amino acids of which at least two amino acids are connected by at least one disulfide group S is a spacer comprising at least 15 carbon atoms D is a detection moiety m, o are integers independently between 1 and 200 n is an integer between 4 and 200 with the provisio that X binds to the antigen binding domain of a chimeric antigen receptor of a cell. The detection agent can be used in a method to detect cells having an antigen binding domain of a chimeric antigen receptor (CAR) binding the detection reagent and preferable to remove the detection moiety D from the detected cell.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: December 22, 2020
    Assignee: Multenyi Biotec, gmbH
    Inventors: Anne Richter, Michaela Niemoller, Volker Nolle, Stefan Miltenyi, Mario Assenmacher
  • Patent number: 10864277
    Abstract: The present invention relates to a method of producing an immunoligand/payload conjugate, which method encompasses conjugating a payload to an immunoligand by means of a sequence-specific transpeptidase, or a catalytic domain thereof.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: December 15, 2020
    Assignee: NBE Therapeutics AG
    Inventors: Ulf Grawunder, Roger Renzo Beerli
  • Patent number: 10851157
    Abstract: Antitumor antagonists that bind specifically to immune checkpoint regulators, angiogenesis pathway regulators and/or TGF pathway regulators are disclosed. Also disclosed are methods for treating proliferative disorders, infections, and immunological disorders with the antitumor antagonists described herein.
    Type: Grant
    Filed: December 6, 2019
    Date of Patent: December 1, 2020
    Assignee: Gensun Biopharma, Inc.
    Inventors: Margaret Karow, Jackie Sheng, Wei Zhang
  • Patent number: 10792342
    Abstract: Methods of making ligand-decorated polymer conjugates of therapeutic glycoproteins are described. Improved targeting of glycoproteins to specific tissues is achieved by masking the natural carbohydrate and other surface determinants with high molecular weight polymers, such as, e.g., PEG, polysialic acid, etc., which in turn are decorated with target-specific ligands. In some embodiments, acid-labile linkages in such conjugates or rapidly degradable masking groups allow for the intracellular release of the polymer from the glycoprotein, for example, under conditions found in lysosomes.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: October 6, 2020
    Assignee: Genzyme Corporation
    Inventor: James Stefano
  • Patent number: 10787480
    Abstract: Disclosed herein are novel cytotoxic peptides of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel cytotoxic peptide linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: September 29, 2020
    Assignee: Novartis AG
    Inventors: Bernhard Hubert Geierstanger, Jan Grunewald, Yunho Jin, Weijia Ou, Tetsuo Uno, Yongqin Wan, Xing Wang
  • Patent number: 10751422
    Abstract: Antibody drug conjugates (ADC's) that bind to FLT3 protein and variants thereof are described herein. FLT3 exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: August 25, 2020
    Assignee: AGENSYS, INC.
    Inventors: Nandini Rudra-Ganguly, Christine Lowe, Faisal Hayat Malik, Sung Ju Moon, Josh Snyder, Hector Avina, Cyrus Virata, Linnette Capo, Gao Liu
  • Patent number: 10676773
    Abstract: An antibody has at a heavy chain thereof a C-terminal extension that includes at least one glutamine that is a substrate for transglutaminase, enabling the transglutaminase-mediated preparation antibody-drug conjugates using such antibody.
    Type: Grant
    Filed: March 1, 2016
    Date of Patent: June 9, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Chetana Rao-Naik, Shrikant Deshpande
  • Patent number: 10668181
    Abstract: A surgical sealant consisting of (1) a first agent comprising a gelatin derivative, wherein the gelatin derivative (a) has a weight average molecular weight of from 10,000 to 50,000; (b) has a hydrophobic group bonded thereto, the hydrophobic group being an alkyl group having 6 to 18 carbon atoms; (c) has a molar ratio of imino group/amino group of the gelatin derivative ranging from 1/99 to 30/70; and (d) comprises a structure represented by the following formula: GltnNH—CHR1R2, wherein “Gltn” represents a gelatin residue, R1 is the hydrophobic group, and R2 is a hydrogen atom or the hydrophobic group; and (2) a second agent comprising a crosslinking agent for the gelatin derivative.
    Type: Grant
    Filed: January 11, 2017
    Date of Patent: June 2, 2020
    Assignee: NATIONAL INSTITUTE FOR MATERIALS SCIENCE
    Inventor: Tetsushi Taguchi
  • Patent number: 10654924
    Abstract: Binding molecules to IL-17A. The binding molecules are useful in the treatment of disorders, for example psoriasis.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: May 19, 2020
    Assignee: CRESCENDO BIOLOGICS LIMITED
    Inventors: Bryan Edwards, Ulla Lashmar, Brian McGuinness, Mike Romanos, Thomas Sandal, Yumin Teng
  • Patent number: 10647745
    Abstract: The present invention provides a compound (I) for treating sequelae of ischemic cerebral stroke: H—(NH—CHR1—CO)—(NH—CHR2—CO)—(NH—CHR3—CO)—(NH—CHR4—CO)—(NH—CHR5—CO)—(NH—CHR6—CO)—(NH—CHR7—CO)—OH??(I) or a pharmaceutically acceptable salt thereof, wherein R1-R7 are defined herein. The present invention also provides a pharmaceutical composition comprising said compound and use of the same in the manufacture of a medicament for treating sequelae of ischemic cerebral stroke. The compound and pharmaceutical composition according to the present invention have good pharmacological activities so that they are able to improve significantly the symptom of sequelae of ischemic cerebral stroke.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: May 12, 2020
    Inventor: Jingyi Wang
  • Patent number: 10639382
    Abstract: The present disclosure relates to methods of reducing the number of abnormal PBMC cells in a leukemia patient. The methods may include administering an effective amount of a drug, which may not be indicated for leukemia, or an antibody-drug conjugate. The antibody-drug conjugate includes an antibody selected from the group consisting of an anti-?2-adrenoreceptor antibody, an anti-? adrenoceptor antibody, an anti-trace amine-associated receptor 1 antibody, an anti-dopamine receptor antibody, and an anti-serotonin receptor antibody; a drug selected from the group consisting of isoproterenol, methyldopa, olanzapine, and a derivative thereof; and a linker that conjugates the antibody and the drug.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: May 5, 2020
    Assignees: National Guard Health Affairs, King Saud bin Abdulaziz University for Health Services, King Abdullah International Medical Research Center
    Inventors: Mohamed Boudjelal, Atef Nehdi, Ahmed Sulaiman Alaskar, Imadul Islam, Hajar Mohammed Alzahrani
  • Patent number: 10617670
    Abstract: This invention relates to combinations of an auristatin or an auristatin-based antibody-drug-conjugate (ADC) with second active agents including PI3K/mTOR inhibitors, MEK inhibitors, taxanes, or other anti-cancer agents, and methods of treating abnormal cell growth by administering these combinations to patients.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: April 14, 2020
    Assignee: Pfizer Inc.
    Inventors: Puja Sapra, Boris Shor
  • Patent number: 10578577
    Abstract: Embodiments of the invention are directed to a solid-state zinc sensor. A non-limiting example of the sensor includes a semiconductor substrate. The sensor can also include an assembly surface on the semiconductor substrate. The sensor can also include a zinc detection monolayer chemically bound to the assembly surface. The sensor can also include a power supply electrically connected to the semiconductor substrate.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: March 3, 2020
    Assignee: INTERNATIONAL BUSINESS MACHINES CORPORATION
    Inventors: Ali Afzali-Ardakani, Abram L. Falk, Bharat Kumar
  • Patent number: 10443026
    Abstract: A polygonal scaffold includes at least three polyproline II (PPII) helix rods and at least three connectors. Each of the PPII helix rods is composed of a plurality of repeat units represented by Formula (i), and at least one of the PPII helix rods has at least one hydrogen atom of at least one of the repeat units being substituted by a first chemical handle for connecting a ligand. Each of the connectors is a divalent organic group, and every two of the PPII helix rods are connected by one of the connectors to form a closed ring. Therefore, with the uniform composition, the PPII helix rods have a stable helical structure under aqueous conditions, and a desired rigidity can be provided.
    Type: Grant
    Filed: December 25, 2017
    Date of Patent: October 15, 2019
    Assignee: NATIONAL TSING HUA UNIVERSITY
    Inventors: Sheng-Kai Wang, Cin-Hao Lin
  • Patent number: 10307488
    Abstract: Disclosed are novel antibody-drug conjugates and use thereof in therapy, in particular in anticancer or anti-inflammatory therapy, as well as synthetic products useful as linkers, composed of a linker head and a linker body, and also a method for preparing the linkers and the antibody-drug conjugates.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: June 4, 2019
    Assignee: UNIVERSITE FRANCOIS RABELAIS
    Inventors: Nicolas Joubert, Marie Claude Viaud-Massuard, Renaud Respaud
  • Patent number: 10307391
    Abstract: The present invention relates to novel disulfur bridge linkers containing hydrazine used for the specific conjugation of compounds/cytotoxic agents to a cell-binding molecule, through bridge linking a pair of thiols on the cell-binding molecule. The invention also relates to methods of making such linkers, and of using such linkers in making homogeneous conjugates, as well as of application of the conjugates in treatment of cancers, infections and autoimmune disorders.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: June 4, 2019
    Assignee: HANGZHOU DAC BIOTECH CO., LTD.
    Inventor: Robert Yongxin Zhao
  • Patent number: 10265291
    Abstract: The present invention relates to novel disulfur bridge linkers containing hydrazine used for the specific conjugation of compounds/cytotoxic agents to a cell-binding molecule, through bridge linking a pair of thiols on the cell-binding molecule. The invention also relates to methods of making such linkers, and of using such linkers in making homogeneous conjugates, as well as of application of the conjugates in treatment of cancers, infections and autoimmune disorders.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: April 23, 2019
    Assignee: HANGZHOU DAC BIOTECH CO., LTD.
    Inventor: Robert Yongxin Zhao
  • Patent number: 10215727
    Abstract: Embodiments of the invention are directed to a solid-state zinc sensor. A non-limiting example of the sensor includes a semiconductor substrate. The sensor can also include an assembly surface on the semiconductor substrate. The sensor can also include a zinc detection monolayer chemically bound to the assembly surface. The sensor can also include a power supply electrically connected to the semiconductor substrate.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: February 26, 2019
    Assignee: INTERNATIONAL BUSINESS MACHINES CORPORATION
    Inventors: Ali Afzali-Ardakani, Abram L. Falk, Bharat Kumar
  • Patent number: 10201615
    Abstract: The present invention is directed to methods for treating cancer comprising administering to a subject in need thereof an auristatin-based antibody drug conjugate and an inhibitor of the PI3K-AKT-mTOR pathway.
    Type: Grant
    Filed: January 27, 2016
    Date of Patent: February 12, 2019
    Assignee: SEATTLE GENETICS, INC.
    Inventors: Timothy S. Lewis, Che-Leung Law, Julie A. McEarchern
  • Patent number: 10159745
    Abstract: Novel tubulysin derivatives which may be useful as cytotoxic agents to provide therapeutic benefits in the treatment of various types of cancers, alone, as drug conjugates or in combination with other chemotherapies are provided.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: December 25, 2018
    Assignee: MedImmune, LLC
    Inventors: Lakshmaiah Gingipalli, Dorin Toader, Fengjiang Wang
  • Patent number: 10117947
    Abstract: The present disclosure is directed to methods and compositions for the diagnosis and/or treatment of tumors, such as ocular tumors, using virus-like particles conjugated to photosensitive molecules.
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: November 6, 2018
    Assignees: Aura Biosciences, Inc., The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Elisabet de los Pinos, John Todd Schiller, Rhonda C. Kines, John MacDougall
  • Patent number: 10118966
    Abstract: The present invention provides a method for producing an anti-EGFR monoclonal antibody and the applications thereof. The method comprises the steps of: designing and synthesizing the light chain and heavy chain according to the codons preferred by Chinese hamster, transfecting GS knockout host cells CHO-CR-GS?/?, culturing cells using serum-free technology, isolating and purifying the antibody, and obtaining the low immunogenicity CMAB009 antibody.
    Type: Grant
    Filed: January 4, 2016
    Date of Patent: November 6, 2018
    Assignee: Shanghai Biomabs Pharmaceuticals Co., Ltd.
    Inventor: Weizhu Qian
  • Patent number: 9943615
    Abstract: Disclosed herein are nanoparticles and method for manufacturing the same. The nanoparticle is essentially composed of albumin and polyethylene glycol, wherein the albumin is covalently crosslinked with the polyethylene glycol.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: April 17, 2018
    Assignee: INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL, EXECUTIVE YUAN R.O.C
    Inventors: Su-Jung Chen, Chang-An Chen, Chung-Yen Li, Chu-Nian Cheng, Ming-Syuan Lin, Shu-Pei Chiu, Chih-Hsien Chang
  • Patent number: 9939447
    Abstract: Compositions, kits, and methods are disclosed for determining one or more target polypeptides in a sample where the target polypeptides have undergone a post-translational modification. The compositions can include a first reagent including a cleavage-inducing moiety and a first binding agent for a binding site that includes a post-translational modification of a target polypeptide.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: April 10, 2018
    Assignee: Monogram Biosciences, Inc.
    Inventors: Sharat Singh, Hossein Salimi-Moosavi, Syed Hasan Tahir, Gerald J. Wallweber, Hrair Kirakossian, Tracy J. Matray, Vincent S. Hernandez
  • Patent number: 9895450
    Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: February 20, 2018
    Assignee: Genentech, Inc.
    Inventors: Eric J. Brown, John Flygare, Wouter Hazenbos, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
  • Patent number: 9884126
    Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.
    Type: Grant
    Filed: May 22, 2014
    Date of Patent: February 6, 2018
    Assignee: Genentech, Inc.
    Inventors: Eric J. Brown, John Flygare, Wouter Hazenbos, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
  • Patent number: 9878041
    Abstract: A tissue adhesive including cyanoacrylate and polyethylene glycol (PEG), wherein the PEG remains a polyether and wherein the tissue adhesive is bioabsorbable. A tissue adhesive including cyanoacrylate bulk monomer and cyanoacrylate nanoparticles containing a therapeutic therein. A kit for applying tissue adhesive, including the tissue adhesive described above and an applicator. Methods of accelerating degradation of a cyanoacrylate tissue adhesive applying a tissue adhesive, closing an internal wound, administering a therapeutic to tissue, treating cancer, and preventing infection in a wound. Methods of method of making a bioabsorbable tissue adhesive and making a therapeutic tissue adhesive.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: January 30, 2018
    Assignee: Adhezion Biomedical, LLC
    Inventors: Jeoung Soo Lee, Charles Kenneth Webb, Robert Zimmerman, Rafael Ruiz, Sr., Sheng Zhang
  • Patent number: 9803002
    Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: October 31, 2017
    Assignee: Genentench, Inc.
    Inventors: Eric J. Brown, Martine Darwish, John Flygare, Wouter Hazenbos, Byoung Chul Lee, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
  • Patent number: 9752137
    Abstract: Compounds, compositions and methods for the preparation of peptide/protein conjugates, said method comprising a step of reacting a compound (2) represented by the formula (2) with a compound (3) represented by the formula (3) to obtain compound (1) represented by the formula (1), wherein R? represents substituent, and R represents H or at least one substituents. Also disclosed is a kit comprising the compound.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: September 5, 2017
    Assignee: THE UNIVERSITY OF HONG KONG SHENZHEN INSTITUTE OF RESEARCH AND INNOVATION
    Inventors: Xuechen Li, Chun Ling Tung, Clarence Tsun Ting Wong
  • Patent number: 9688721
    Abstract: Tubulysin compounds of the formula (I) where R1, R2 R3a, R3b, R4, R5, W, and n are as defined herein, are anti-mitotic agents that can be used in the treatment of cancer, especially when conjugated to a targeting moiety.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: June 27, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Qiang Cong, Heng Cheng, Sanjeev Gangwar
  • Patent number: 9675715
    Abstract: There is provided a contrast agent for photoacoustic imaging, the contrast agent exhibiting high tumor accumulation and high photoacoustic signal intensity even when time has passed since administration. A contrast agent for photoacoustic imaging comprises a complex including albumin covalently bound to an organic dye that absorbs light in the near-infrared wavelength region.
    Type: Grant
    Filed: July 17, 2013
    Date of Patent: June 13, 2017
    Assignee: CANON KABUSHIKI KAISHA
    Inventors: Atsushi Takahashi, Satoshi Ogawa, Fumio Yamauchi, Kengo Kanazaki, Daisuke Sasaguri, Masato Minami
  • Patent number: 9580495
    Abstract: Severe glomerulonephritis involves cell necrosis as well as NETosis, programmed neutrophil death leading to expulsion of nuclear chromatin and neutrophil extracellular traps (NETs). Histones released by neutrophils undergoing NETosis killed glomerular endothelial cells, podocytes, and parietal epithelial cells. This was prevented by histone-neutralizing agents anti-histone IgG, activated protein C and heparin. Histone toxicity on glomeruli was TLR2/4-dependent. Anti-GBM glomerulonephritis involved NET formation and vascular necrosis. Pre-emptive anti-histone IgG administration significantly reduced all aspects of glomerulonephritis, including vascular necrosis, podocyte loss, albuminuria, cytokine induction, recruitment and activation of glomerular leukocytes and glomerular crescent formation.
    Type: Grant
    Filed: June 23, 2015
    Date of Patent: February 28, 2017
    Assignee: Immunomedics, Inc.
    Inventors: Santhosh V. R. Kumar, Hans-Joachim Anders
  • Patent number: 9511140
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Grant
    Filed: March 8, 2016
    Date of Patent: December 6, 2016
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Daniel Dix, Kelly Frye, Susan Kautz
  • Patent number: 9498541
    Abstract: Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: November 22, 2016
    Assignee: ImmunoGen, Inc.
    Inventors: Ravi V. J. Chari, Robert Yongxin Zhao, Yelena Kovtun, Rajeeva Singh, Wayne C. Widdison
  • Patent number: 9493504
    Abstract: The present invention relates to the field of radiopharmaceuticals for in vivo imaging, in particular to a method of labelling a biological targeting molecule with a radioisotope. The method of the invention is particularly suitable for use with an automated synthesizer apparatus. Also provided are precursors in sterile form, as well as cassettes comprising such precursors useful in the method.
    Type: Grant
    Filed: December 1, 2011
    Date of Patent: November 15, 2016
    Assignee: GE Healthcare Limited
    Inventor: Bard Indrevoll
  • Patent number: 9181235
    Abstract: The present invention relates to compositions and methods for modulating the Wnt signaling pathway, using compounds having Formula (1) and (3): wherein A, B, Y and Z all represent rings, and R1, R2, R3 are as defined herein.
    Type: Grant
    Filed: June 28, 2011
    Date of Patent: November 10, 2015
    Assignee: NOVARTIS AG
    Inventors: Dai Cheng, Guobao Zhang, Dong Han, Wenqi Gao, Shifeng Pan, Lichun Shen, Rajender Reddy Leleti
  • Patent number: 9102730
    Abstract: The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.
    Type: Grant
    Filed: April 29, 2013
    Date of Patent: August 11, 2015
    Assignee: Baylor Research Institute
    Inventors: Gerard Zurawski, Jacques F. Banchereau, Eynav Klechevsky, Sandra Zurawski, Anne-Laure Flamar
  • Patent number: 9044518
    Abstract: The present invention relates to new auristatin compounds and prodrugs thereof, compositions comprising them and uses thereof.
    Type: Grant
    Filed: March 29, 2012
    Date of Patent: June 2, 2015
    Assignee: ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: George R. Pettit, Fiona Hogan, Steven Toms
  • Publication number: 20150140022
    Abstract: A compound comprising a photosensitizer covalently coupled to a protein selected from the group consisting of antibodies or their derivatives or fragments thereof, synthetic peptides such as scFv, mimotopes which bind CD antigens, cytokine receptors, interleukin receptors, hormone receptors, growth factor receptors, more particularly tyrosine kinase growth factor receptor of the ErbB family, wherein the photosensitizer is coupled to the binding protein via O6-alkylguanine-DNA alkyltransferase (hAGTm), a modified human DNA repair protein.
    Type: Application
    Filed: March 21, 2012
    Publication date: May 21, 2015
    Inventors: Stefan Barth, Mehmet K. Tur, Ahmad Hussain
  • Publication number: 20150139947
    Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.
    Type: Application
    Filed: October 31, 2014
    Publication date: May 21, 2015
    Applicant: BIOGEN IDEC HEMOPHILIA INC.
    Inventors: ROBERT T. PETERS, ADAM R. MEZO, DANIEL S. RIVERA, ALAN J. BITONI, SUSAN C. LOW
  • Publication number: 20150132324
    Abstract: Tubulysin compounds of the formula (I) where R1, R2, R3a, R3b, R4, R5, W, and n are as defined herein, are anti-mitotic agents that can be used in the treatment of cancer, especially when conjugated to a targeting moiety.
    Type: Application
    Filed: January 26, 2015
    Publication date: May 14, 2015
    Inventors: Qiang CONG, Heng Cheng, Sanjeev Gangwar
  • Patent number: 9028833
    Abstract: The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy.
    Type: Grant
    Filed: July 23, 2013
    Date of Patent: May 12, 2015
    Assignee: Immunomedics, Inc.
    Inventors: Serengulam V. Govindan, David M. Goldenberg